Responsible by design
Responsible by design
Responsible by design

 

Responsible by design is how SCILEX leads by example. We’re committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them most. With a passion for patients and a dedication to innovation, SCILEX is lighting the way forward in pain management.

 
Lighting the way forward
Lighting the way forward
Lighting the way forward

Latest
SCILEX news

Scilex Announces Addition of ZTlido® to Express Scripts National Formularies

SAN DIEGO, Jan. 14, 2019 (GLOBE NEWSWIRE) — Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), today announced that Express Scripts has added ZTlido® (lidocaine topical system) 1.8% to its commercial national formularies representing nearly 30 million lives.  ZTLIDO is indicated for relief of pain associated with postherpetic neuralgia (PHN), also … Continue reading Scilex Announces Addition of ZTlido® to Express Scripts National Formularies

 

Re-engineering pain management

At SCILEX, we believe that innovation is the path to improving therapeutic outcomes in pain management. We believe our advances in this area are evidence of our tireless dedication to optimizing the patient experience.

X

Share This Page

XS SM MD LG XL